Ticho Barry: insider trades.
Ticho Barry reported 9 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 8 sales ($767K), across 1 company.
- Transactions
- 9
- Purchases (P)
- 0
- Sales (S)
- 8
- Companies
- 1
- Name as filed
- Ticho Barry
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | Officer · CHIEF MEDICAL OFFICER | 9 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-01 | Stoke Therapeutics, Inc. | S | 1,600 | $31.06 | 20,110 | Form 4 |
| 2026-09-01 | Stoke Therapeutics, Inc. | S | 3,945 | $30.51 | 21,710 | Form 4 |
| 2026-08-18 | Stoke Therapeutics, Inc. | S | 242 | $32.47 | 25,655 | Form 4 |
| 2026-08-18 | Stoke Therapeutics, Inc. | S | 4,525 | $32.01 | 25,897 | Form 4 |
| 2026-08-14 | Stoke Therapeutics, Inc. | M | 10,000 | $0 | 30,422 | Form 4 |
| 2026-08-03 | Stoke Therapeutics, Inc. | S | 5,907 | $28.95 | 21,691 | Form 4 |
| 2026-08-03 | Stoke Therapeutics, Inc. | S | 1,269 | $29.45 | 20,422 | Form 4 |
| 2026-07-01 | Stoke Therapeutics, Inc. | S | 500 | $33.27 | 27,598 | Form 4 |
| 2026-07-01 | Stoke Therapeutics, Inc. | S | 6,728 | $32.62 | 28,098 | Form 4 |
Questions
What stock did Ticho Barry buy or sell?
Ticho Barry reported 9 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 8 sales ($767K), across 1 company.
Is Ticho Barry the same person as other filers with this name?
This page covers SEC CIK 1780088 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/ticho-barry-1780088.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.